EpiQMAx is a German company that provides a service platform for enabling the discovery and validation of epigenetic drugs and epigenetic biomarkers associated with diseases, aging, lifestyle, and other biological conditions. EpiQMAx expertise focuses on the detection and quantification of histone modifications from different sample sources including blood, plasma, saliva, buccal swabs, tissue, and cell lines. EpiQMAx solutions are based on mass spectrometry, which allows multiplexing, specific, high-throughput screening of histone epigenetic marks. In addition to it, we offer solutions for characterization and quantification of post-translational modifications on whole proteomes or specific protein subsets. Complemented with data analysis and visualization tools, EpiQMAx provides complete fee-for-service solutions that go from sample preparation to marker quantification and reporting of results. Our clients range from research institutes to pharma/biotech companies.